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OBJECTIVES This study was designed to evaluate the composition and quantity of particulate debris
resulting from vein graft intervention.
BACKGROUND Distal embolization and “no reflow” are frequent and important complications resulting from
angioplasty of diseased saphenous vein grafts. Little is known about the composition and
quantity of embolic particulate debris associated with vein graft intervention, and no
intervention has been shown to protect against its clinical consequences.
METHODS A catheter system, designed to contain, retrieve and protect against distal embolization of this
material, was evaluated during 27 percutaneous interventional saphenous vein graft proce-
dures. Clinical, angiographic and pathologic analyses were performed.
RESULTS The duration of distal graft occlusion required to allow intervention and subsequent debris
removal was 150 6 54 s, decreasing as experience was gained. Thrombolysis in Myocardial
Infarction trial (TIMI) flow grade increased from 2.6 6 0.8 to 3.0 6 0.0. Creatine kinase
(CK) rose above normal in three patients (11.1%) exceeding 33 normal in one (3.7%)
resulting in the diagnosis of non-Q-myocardial infarction. Particulate material was identified
following 21 of 23 procedures suitable for analysis. Particle size was 204 6 57 mm in the
major axis and 83 6 22 mm in the minor axis. Particles consisted predominantly of soft
acellular atheromatous material, such as that typically found under a fibrous cap. Semiquan-
titative analysis suggested that the quantity of particulate material was less following stenting
than following balloon dilation.
CONCLUSIONS Particulate matter is commonly present following routine angioplasty and stenting of
saphenous vein grafts. Containment, retrieval and analysis of this particulate debris are all
feasible. Comparison to prior clinical experience is limited by small sample size. However, to
the extent that these particles may contribute to distal embolization, no-reflow and infarction,
such a system may contribute to the reduction of complications following vein graft
intervention. (J Am Coll Cardiol 1999;34:468–75) © 1999 by the American College of
Cardiology
A limitation of coronary bypass surgery has been the
relatively rapid progression of atheromatous disease in
aortocoronary saphenous vein grafts (1). More than one-
half of such grafts have failed by 10 years, and the risk of
repeat surgery is significantly greater than that of the initial
procedure (2,3).
Interventional management of saphenous vein graft dis-
ease is limited by distal embolization (4,5) and “no-reflow”
(6–10), which may arise from disruption of soft, friable
atherosclerotic plaque and adherent thrombus (11,12). The
reported incidence of distal embolization following balloon
angioplasty ranges from 2% to 42%, contributing to sub-
stantial morbidity (4,6,13–17). Recognized predictors of
distal embolization and infarction include the presence of
diffuse disease, plaque volume, and thrombus (17). Little
information is available about the composition of this
particulate material, and no method has been shown to
prevent distal embolization. We describe a catheter system
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designed to contain and retrieve this particulate material,
the clinical and angiographic outcome following application
of this system and analysis of the composition of this
particulate material.
METHODS
Experimental protocol. Between July 1997 and April
1998, a total of 22 consecutive eligible patients underwent
27 vein graft angioplasty procedures utilizing a device
(PercuSurge, Sunnyvale, California) designed to contain
and retrieve potentially embolic particulate material. Pa-
tients were considered eligible if they were between 35 and
85 years of age with evidence of ischemia and had a .70%
diameter stenosis ,30 mm in length, with TIMI flow grade
$1 in a saphenous vein graft 3.5 to 5 mm in diameter.
Exclusion criteria included myocardial infarction ,72 h
before the procedure, uncontrolled heart failure, cardiogenic
shock, coagulation disorders or a contraindication to hepa-
rin. Informed consent was obtained, and the protocol was
approved by the appropriate investigational review commit-
tees.
Device description. The particulate containment and re-
trieval system consists of several components, as shown in
Figure 1. The 210-cm angioplasty wire is constructed of
0.014 in. nitinol hypotube with a 35-mm radiopaque,
shapeable, steerable tip. Incorporated in the distal wire is a
5.5-mm-long elastomeric balloon with a 0.41 to 0.43 in.
crossing profile and available inflated diameters of 3.5 to
5.0 mm (Fig. 2). A detachable inflation adapter accesses the
hypotube lumen by displacing a small seal, allowing infla-
tion of the balloon. An aspiration catheter (Export, Percu-
Surge, Sunnyvale, California) with an internal lumen diam-
eter of 0.040 in. allows removal of particulate debris before
deflation of the occlusive balloon. The 135-cm-long aspi-
ration catheter has a 35-cm-long distal monorail wire lumen
and an external diameter of 0.072 in.
The occlusion balloon was advanced through the graft
and distal to the stenosis. The inflation adapter was tem-
porarily attached and the distal occlusion balloon inflated.
Following removal of the inflation adapter, intervention was
performed in a standard manner utilizing the hypotube as
the angioplasty guide wire (Fig. 3). After removal of the
interventional device, the aspiration catheter was advanced
over the wire to the occlusion balloon. A 20-ml locking
syringe was attached to the aspiration catheter to generate a
vacuum and to serve as the collection chamber. Following
manual aspiration, the inflation adapter was again attached
Abbreviations and Acronyms
CK 5 creatine kinase
ECG 5 electrocardiogram
TIMI 5 Thrombolysis in Myocardial Infarction trial
Figure 1. Schematic of the particulate retrieval system.
Figure 2. Photograph of distal occlusion balloon and aspiration
catheter.
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and the distal occlusion balloon deflated, thus allowing
coronary flow to resume.
Angioplasty procedure. Angioplasty was performed utiliz-
ing 8F guides with an internal lumen of 0.086 in. and
monorail balloon catheters (Boston Scientific, Galway, Ire-
land). Initial patients underwent balloon predilation prior to
stent deployment. Subsequent patients later underwent
primary stenting without predilation. Nir (Boston Scien-
tific, Jerusalem, Israel), biliary Palmaz-Schatz (Johnson &
Johnson Interventional Systems, Warren, New Jersey),
Multilink (Guidant, Temecula, California), and BeStent
(Medtronic Instent, Haifa, Israel) stents measuring 9 mm to
35 mm in length were implanted. Stents were dilated
utilizing the initial deployment balloon inflated to at least
12 atmospheres with a goal balloon-to-reference segment
ratio of .1.1:1.
Patients were pretreated with aspirin 325 mg daily.
Ticlopidine 500 mg daily was initiated following the pro-
cedure and continued for two weeks. Heparin was admin-
istered to achieve an activated clotting time exceeding 300 s
and routinely discontinued immediately on completion.
Abciximab was utilized in four patients. Dextran, dipyrid-
amole, warfarin, thrombolytics, calcium channel blockade
and nitroglycerin were not routinely utilized.
Angiographic assessment. Angiograms, performed in or-
thogonal views at baseline and after the intervention, were
quantitatively analyzed at an independent core laboratory
(Vancouver General Hospital). Thrombus was judged to be
present if contrast angiography demonstrated an intralumi-
nal filling defect or an abrupt vessel cutoff. “No-reflow” was
defined as a new, severe reduction in coronary flow to TIMI
grade 0 or 1 not due to local thrombus, spasm or dissection,
implying obstruction at the level of the distal small vessels
(18). Distal embolization was diagnosed when there was a
filling defect, no reflow, or an abrupt cutoff in a distal
coronary artery branch.
Pathologic assessment. Vein graft aspirate was collected in
glass tubes containing EDTA-citrate buffer and transported
on ice. Samples were centrifuged, the plasma removed and
the pellet resuspended in incomplete Hank’s Balanced Salt
Solution without calcium and magnesium. Erythrocytes
were lysed with 1% saponin. The reaction was stopped by
calcium gluconate, and samples were then centrifuged,
resuspended and the lysis step repeated. The remaining
material was fixed in 10% neutral buffered formalin or
glutaraldehyde and processed for light microscopy and
scanning electron microscopy.
Semiquantitative analysis was performed on 4-mm-thick
paraffin-embedded sections stained with hematoxylin and
eosin. Samples were considered to have maximal tissue if
some atherosclerotic material was present in every high
power field of the section of the precipitate, moderate if
every other field showed some atherosclerotic material, and
minimal when only sparse material was evident. Particle size
was measured from scanning electron micrographs contain-
ing a calibrated bar. The major and minor lengths and area
of each particle were determined using computer software
(IP Labs, Signal Analytics, Vienna, Virginia).
Clinical outcomes. Total creatine kinase (CK) and crea-
tine kinase, MB fraction (CK-MB) were measured before
angioplasty, 8 h, and 16 h postangioplasty. An electrocar-
diogram (ECG) was obtained before angioplasty, immedi-
ately following angioplasty, if chest discomfort recurred and
the following morning. Myocardial infarction was defined
as an elevation of CK to .33 normal associated with
elevation of CK-MB (19). Q-wave infarction was diagnosed
in the presence of new Q waves in two contiguous leads.
Clinical follow-up was obtained prospectively, by chart
review and by telephone.
Statistical analysis. Results are reported as mean 6 SEM.
Comparisons between angiographic measurements were
made with a paired t tests. Group comparisons were
performed by factorial ANOVA (STATVIEW 4.5, Abacus
Concepts, San Francisco, California) and analyzed simulta-
neously with post hoc testing by the Scheffe´ procedure.
Statistical significance was defined as p , 0.05.
RESULTS
Between July 1997 and April 1998, a total of 27 vein graft
interventions were performed utilizing an emboli contain-
ment device (Table 1). Patient age was 64 6 10 years and
graft age 8.7 6 5 years (range 2 to 12 years). Procedure time
was 65 6 25 min and fluoroscopy time 18 6 10 min. Distal
graft occlusion averaged 150 6 54 s, decreased as experience
was gained and was well tolerated. Occlusion balloon
inflation volume was 1.1 6 0.02 ml. Mean aspirate volume
was 19.1 6 5.3 ml.
Figure 3. Diagrammatic representation of the mechanism of
particulate containment and retrieval.
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Clinical outcome. All 27 procedures were technically suc-
cessful, as shown in Figure 4. A total of 37 lesions were
treated with implantation of 36 stents. No patient developed
new Q waves, required cardiac surgery, or died. Creatine
kinase remained normal (,260 U/liter) following 24 of 27
procedures and rose above normal following 3 procedures
(11.1%). In one of these patients (CK 492 U/liter) a large
visible thrombus was dislodged prior to distal occlusion with
the GuardWire (PercuSurge Inc., Sunnyvale, California). In
a second patient (CK 285 U/liter) operator error resulted in
premature deflation of the occlusion balloon prior to aspi-
ration. In a third patient (CK 1201 U/liter) with a large,
bulky thrombus, no-reflow was evident despite protection,
presumably due to incomplete thrombus aspiration. In this
patient CK exceeded 33 normal, resulting in the diagnosis
of non-Q myocardial infarction (3.7%). At 6 6 3 months,
no patient had died, suffered late infarction or undergone
cardiac surgery, whereas target lesion reintervention was
undertaken in three patients.
Angiographic results. Qualitative and quantitative angio-
graphic results are presented in Table 2. In no patient was
the occlusion balloon associated with visible damage to the
distal vessel. Follow-up angiography performed in nine
patients at 5 6 3 months found restenosis (stenosis .50%)
in four grafts, TIMI flow grade 2.9 6 0.4 and no evidence
of new disease at the site of distal occlusion.
Pathologic assessment. A total of 49 aspirations were
suitable for analysis. Particulate material was retrieved from
21 of 23 procedures. Light microscopy revealed that the
particles consisted predominantly of necrotic core with
cholesterol clefts, lipid-rich macrophages and fibrin material
(Fig. 5). Fibrous caps and smooth muscle cells were iden-
tified, but these appeared relatively sparse. This suggested
the material consisted primarily of the soft acellular ather-
omatous material typically found under the fibrous cap
(Table 3). Scanning electron microscopy found a particle
size of 204 6 57 mm (range 8 to 3,427 mm) in the major axis
and 83 6 22 mm in the minor axis (Fig. 6).
Semiquantitative analysis of aspirates, as shown in Table
3, found both balloon angioplasty and stenting were asso-
ciated with recovery of particulate debris. However, partic-
ulate material was significantly greater following balloon
predilation than subsequent stenting (p 5 0.43). Direct
stenting without balloon predilation was associated with
less particulate material than seen with balloon predila-
tion alone and less than that associated with the combi-
Table 1. Baseline Clinical Characteristics
Characteristic n (%)
Male gender 18 66
Diabetes 3 11
Hyperlipidemia 14 52
Angina class 3 or 4 16 59
Prior Q-wave infarction 12 44
Infarction within 1 year 5 19
Vein graft distribution
left anterior descending 7 26
circumflex 7 26
right coronary 13 48
Figure 4. (A) Angiogram demonstrates ulcerated stenosis in a 10-year-old graft to a circumflex coronary artery. (B) During angioplasty
the occlusive distal balloon prevents graft outflow. Before deflation of the distal occlusion balloon, particulate debris is aspirated and
removed. (C) The graft is widely patent with normal flow.
Table 2. Angiographic Outcome After 27 Procedures
Preprocedure Postprocedure
TIMI flow grade 2.6 6 0.8 3.0 6 0.0
0 1 0
1 2 0
2 5 1
3 19 26
Definite thrombus 10 1
Distal embolism — 1
Transient no-reflow — 3
Reference vessel diameter 3.6 6 0.7 mm 3.7 6 0.6 mm
Minimum lesion diameter 0.8 6 0.6 mm 2.8 6 0.8 mm
% Diameter stenosis 79 6 15% 27 6 21%
Dilated length — 32.6 6 14.9 mm
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nation of balloon predilation and subsequent stenting.
Although suggestive, numbers were small and not statis-
tically significant.
DISCUSSION
Study findings and implications. The principal finding of
our study is that embolic atherothrombotic particulate
matter is commonly liberated during angioplasty and stent-
ing of saphenous vein grafts. This particulate matter may
play a role in the pathogenesis of distal embolization,
no-reflow and infarction following vein graft intervention.
Particulate retrieval procedure. The GuardWire system is
compatible with routine angioplasty procedures and is
capable of containing and then retrieving particulate debris.
Event rates, including CK elevation (11.1%) and non-Q-
wave myocardial infarction (3.7%), were lower than gener-
ally reported following vein graft angioplasty without such
protection (17,19–21). In no case was vessel damage seen as
a result of inflation of the distal occlusive balloon, and late
development of a stenosis at the site of distal occlusion was
not apparent.
Ischemic times required for distal occlusion and aspira-
tion during angioplasty were well tolerated, averaging
2.5 min. Initial patients in this series underwent a staged
procedure with graft aspiration and deflation of the distal
occlusion balloon following predilation and stent deploy-
ment. Because these brief periods of graft occlusion were
Figure 5. Representative micrographs of plaque material from vein graft aspirates. (A) Fibrous cap (FC) overlying a lipid-rich necrotic core
(NC) containing numerous cholesterol clefts (arrows, Movat Pentachrome, 3200). (B) Section stained using the monoclonal antibody
CD68/KP-1 (Dako Inc., Carpinteria, California) for recognition of resident macrophages (dark brown reaction product, 3200). (C)
Immunostaining of aspirate material with the antibody HHF-35 (Enzo Inc., Farmingdale, New York) for recognition of smooth muscle
cells (brown reaction product); note the paucity of staining (3100). (D) Necrotic core with plaque hemorrhage (red cells and fibrin, 3200).
(E) Aspirate material showing strands of collagen (arrow, H&E stain, 3200). (F) Lipid-rich core area with cholesterol clefts (arrows,
H&E stain, 3200).
Table 3. Semiquantitative Analysis of Plaque Material in Vein Graft Aspirates
Samples N Foam Cells
Necrotic
Core
Cholesterol
Clefts Collagen Platelets
Overall
Plaque
Material
Balloon predilation 14 1.21 6 0.21 2.21 6 0.24 1.14 6 0.31 0.64 6 0.20 0.07 6 0.07 1.86 6 0.23
Stenting after predilation 12 1.0 6 0.01 1.67 6 0.23 0.42 6 0.19 0.17 6 0.11 0.83 6 0.83 1.15 6 0.10*
Single-stage stenting without
predilation
7 1.14 6 0.26 1.57 6 0.30 0.57 6 0.30 0.57 6 0.20 1.14 6 0.51 1.27 6 0.49
Comparison of aspirates was obtained following balloon predilation, subsequent stenting and direct stenting without balloon predilation. Semiquantitative analysis was performed
on paraffin-embedded sections stained with hematoxylin and eosin. Scores were recorded as maximal (3), moderate (2), minimal (1) or absent (0) plaque material as defined in
text. *Statistical differences among the three groups by repeated measures ANOVA were only observed in overall plaque material between balloon predilation versus stenting after
predilation (p 5 0.043). The p-value for samples comparing balloon predilation versus stenting without predilation was 0.066, and for stenting after predilation versus stenting
without predilation it was 0.604.
N 5 cases examined.
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well tolerated in early cases, a single-stage approach subse-
quently proved feasible and desirable.
Stenting of vein grafts. All patients in this series under-
went stent implantation. Initial studies of the Palmaz-
Schatz stent in focal vein graft stenoses reported transient
no-reflow in approximately 10% of procedures (22) and a
10% to 12% incidence of non-Q-wave myocardial infarction
(22–26). The Saphenous Vein De Novo Trial (27) com-
pared the Palmaz-Schatz stent to balloon angioplasty and
found a trend toward less non-Q-wave infarction (2% vs.
7%, p 5 0.1). In one series, the Palmaz-Schatz biliary stent
was associated with distal embolization in 23% of patients
and non-Q-wave infarction in 44% (28). De Jaegere (29)
reported a 11% incidence of in-hospital infarction, urgent
surgery or death in a group of patients primarily treated with
the Wallstent. Limited experience has been reported with
the Wallstent (29–31), Wiktor (32), and Gianturco-Roubin
stents (33) and covered stents (34).
Cardiac enzymes. Cardiac enzymes rise in 5% to 20% of
patients following percutaneous coronary interventions in
native vessels (19). The reported frequency of enzyme
elevation following vein graft intervention is generally
higher (17,19–21,34,35) in contrast to the 11.1% incidence
of CK elevation and 3.7% incidence of non-Q-wave infarc-
tion (CK .33 normal) in this study. There is some debate
as to a cause–effect relationship between elevations of CK,
CK-MB, and adverse late clinical outcome (19).
Comparison to alternative strategies. Direct aspiration
has been reported of angiographically visible thrombus from
vein grafts utilizing standard angioplasty guiding catheters
(36–38) and specially constructed thrombo-suction devices
(39,40). Experience with directional atherectomy, laser and
rotablator in vein grafts has been disappointing (41–45).
Transluminal extractional atherectomy (InterVentional
Technologies, Bellevue, Washington) may reduce cardiac
enzyme release following graft intervention; however, expe-
rience has been variable, and distal embolization remains a
concern (13,46–50).
Fibrinolytic drugs have been advocated as adjuncts to vein
graft intervention, and local fibrinolysis has been utilized to
debulk intragraft thrombus. However, reduced embolic
complications have not been demonstrated (51,52). Glyco-
protein IIb/IIIa inhibition may be desirable (53,54). In the
EPIC trial, abciximab was associated with a reduction in
distal embolization and a nonsignificant trend (14% vs. 5%)
toward reduced infarction in the subgroup of patients
undergoing vein graft intervention (55). However, when
results of both the EPIC and EPILOG trials were com-
bined, no benefit was found in patients undergoing vein
graft intervention (53). Although secondary platelet activa-
tion by particulate matter is possible, the large amount of
particulate atheroembolic material demonstrated in our
study suggests a limited role for antiplatelet therapies in the
prevention of distal embolization in saphenous grafts.
Implications for stenting. The quantity of particulate
debris retrieved after balloon predilation was greater than
that retrieved after subsequent stent deployment (Table 3).
This supports conjecture that the screen-like configuration
of stents may entrap friable material, reducing the likelihood
of dislodgment and embolization (27,50). An antiembolic
role for stents may have implications for optimal stent
design. Greater surface coverage might be desirable for
stents designed for use in vein grafts.
The quantity of particulate matter retrieved in patients
who underwent balloon predilation and subsequent stenting
may be greater than that retrieved in patients undergoing
direct stenting without predilation. This finding suggests
that balloon predilation before stenting may increase em-
bolic debris (50) and that direct stent implantation without
predilation may be desirable where possible. However, all
interventions were associated with the recovery of particu-
late debris.
Study limitations. This single-center study is limited by
small size, by limited angiographic follow-up, semi-
quantitative analysis of particulate material and the lack of a
randomized control group. Comparison with prior studies
must be made with caution. The possibility that some of the
aspirated debris might have been removed directly from the
graft wall, as opposed to the lumen, cannot be excluded,
Figure 6. Representative scanning electron micrographs of vein
graft aspirate. (A) Shows tissue resembling a fibrous cap; the
sample possibly rolled during removal or processing (scale 5
20 mm). (B) Fragment of plaque material containing numerous
cholesterol-laden macrophages; the rod-shaped fragment in the
upper left is a cholesterol crystal (arrow, scale 5 50 mm). (C)
Particle showing a cluster of macrophages (scale 5 10 mm). (D)
Macrophages interspersed in a fragment of atherosclerotic plaque
(scale 5 20 mm).
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although the direct effect of the aspiration catheter on the
vein graft wall would be comparable to passage of other
catheters commonly used during coronary interventions.
There remains the potential risk for graft embolization
during passage of the device before distal occlusion or to
incomplete removal of debris. Further clinical trials will
require direct comparison with routine vein graft interven-
tion.
Finally, embolic atherothrombotic particulate matter is
commonly present within saphenous vein grafts following
routine angioplasty and stenting. Containment and retrieval
of embolic particulate matter is feasible, and further trials of
protection devices appear warranted. This particulate matter
may play a role in the pathogenesis of distal embolization,
no-reflow and infarction following vein graft intervention.
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